anti-TROP2/anti-CDH17/anti-CD3 trispecific T-cell engager(Boehringer Ingelheim)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug Nameanti-TROP2/anti-CDH17/anti-CD3 trispecific T-cell engager(Boehringer Ingelheim)
Drug Alias Nameanti-TROP2/anti-CDH17/anti-CD3 trispecific antibody(Boehringer Ingelheim)anti-TROP2/anti-CDH17/anti-CD3 trispecific binding molecule(Boehringer Ingelheim)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-Trop-2Anti-Cadherin-17Anti-CD3
TargetsCadherin-17T cell surface glycoprotein CD3Tumor-associated calcium signal transducer 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A